LATEST RESEARCH NEWS BY ONCOTARGET:
- Next-Generation Antibodies for Cancer TherapyCancer research has made remarkable progress in recent years, with monoclonal antibody (mAb) therapy emerging as one of the most promising advancements. These treatments are designed to precisely target cancer cells, offering a more focused approach that helps patients fight different malignancies with fewer side effects compared to traditional chemotherapy.
- Tribute to Dr. Mikhail (Misha) BlagosklonnyIt is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
- Targeting Stem Cell-like Traits: How miR-10b Inhibition Treats Metastatic Breast CancerIn this study, researchers shared findings showing that inhibiting miR-10b impairs breast cancer cell stemness.
ABOUT ONCOTARGET.ORG:
Oncotarget.org publishes weekly articles describing new and trending research papers published by Oncotarget—an open access biomedical journal dedicated to the publishing of the latest oncology-focused, peer-reviewed research papers. Visit Oncotarget.net to hear directly from the distinguished network of authors who continue to publish their research with Oncotarget. Readers may also find information about community news and events sponsored by Oncotarget at Oncotarget.net.
ABOUT ONCOTARGET:
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Oncotarget is published by Impact Journals, based out of Orchard Park, New York. Impact Journals has a proven track record for reaching the standards of the Wellcome Trust Publisher Requirements and is included in their Wellcome Trust List of Compliant Publishers. Read about our rigorous Scientific Integrity Process.
The Editorial Board of Oncotarget is honored to feature several Nobel Prize winners. The Editorial Board also features winners of prestigious recognitions such as the Lasker Award and the Breakthrough Prize.
Oncotarget utilizes an open-access model. This means that the peer-reviewed research articles published in Oncotarget are distributed online, free of cost or other access barriers. Oncotarget’s mission has always been to make exceptional discoveries rapidly and widely available, eliminate borders between specialties by linking different fields of biomedical science to foster the applications of basic and clinical science.
CONTACT INFORMATION:
For those interested in learning more about Oncotarget or in contacting the Journal, please visit the website.
For media inquiries, please contact media@impactjournals.com.